SCHEMBL5536338

SCHEMBL5536338

[O]c1ccc(N2CCC(Nc3ccccc3Cl)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.49
▸ PKM P14618 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ DCTPP1 Q9H773 1/20 0.42
▸ GFER P55789 1/20 0.41
▸ CNR1 P21554 2/20 0.40
▸ ME3 Q16798 2/20 0.39
▸ EPHX2 P34913 1/20 0.38
▸ PAK1 Q13153 1/20 0.38
▸ GAA P10253 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ACLY P53396 1/20 0.38
▸ SCN8A Q9UQD0 1/20 0.38
▸ DGAT1 O75907 1/20 0.38
▸ MALT1 Q9UDY8 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543879 0.89 KMT2A (0.40) KMT2APKMALDH1A1LMNATP53
SCHEMBL5536343 0.86 ME3 (0.50) KMT2APKMALDH1A1LMNATP53
SCHEMBL5536635 0.83 MAPT (0.41) KMT2AALDH1A1LMNAMAPTCNR1
SCHEMBL5535582 0.83 GAA (0.53) KMT2APKMALDH1A1LMNATP53
SCHEMBL5538936 0.83 MEN1 (0.44) KMT2AALDH1A1LMNATP53MAPT
SCHEMBL5544169 0.80 DRD2 (0.51) ALDH1A1LMNAMAPTGAAKDM4E
SCHEMBL5544308 0.80 SCD (0.57) KMT2APKMMAPTEPHX2GAA
SCHEMBL5534878 0.79 ME3 (0.47) KMT2AALDH1A1MAPTME3EPHX2
SCHEMBL5546298 0.78 HPGD (0.43) KMT2AALDH1A1LMNAMAPTGAA
SCHEMBL5541081 0.78 SCD (0.46) MAPTCNR1ME3EPHX2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMT2A 4267/4885PKM 4291/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback